CHEK2 and breast cancer: The estimated lifetime risk of acquiring breast cancer with an ATM, CHEK2, PALB2 mutation is greater than 20% which is considered a “moderate risk” compared to the effects of the pathogenic variants in BRCA1 and BRCA2 genes with a lifetime risk of approximately 50%.